Cell proliferation in the normal mouse mammary gland and inhibition by phenylbutyrate

Molecular Cancer Therapeutics

Volumn 1, Issue 12, 2002, Pages 1025-1033

  Kennedy, Catherine ^a   Byth, Karen ^a   Clarke, Christine L ^a   DeFazio, Anna ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; 4-PHENYLBUTYRIC ACID; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BROXURIDINE; CYCLIN D1; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; HISTONE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL DIVISION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; UDDER;

ANIMALS; ANTINEOPLASTIC AGENTS; BROMODEOXYURIDINE; CELL DIVISION; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR ALPHA; FEMALE; HISTONES; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED BALB C; PHENYLBUTYRATES; RECEPTORS, ESTROGEN;

EID: 1842870499     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., Barfoot, R., Hamoudi, R., Patel, S., Rice, C., Biggs, P., Hashim, Y., Smith, A., Connor, F., Arason, A., Gudmundsson, J., Ficenec, D., Kelsell, D., Ford, D., Tonin, P., Bishop, D. T., Spurr, N. K., Ponder, B. A. J., Eeles, R., Peto, J., Devilee, P., Cornelisse, C., Lynch, H., Narod, S., Lenoir, G., Egilsson, V., Barkadottir, R. B., Easton, D. F., Bentley, D. R., Futreal, P. A., Ashworth, A., and Stratton, M. R. Identification of the breast cancer susceptibility gene BRCA2. Nature (Lond.), 378: 789-792, 1995. (Pubitemid 26004412)
2. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., McClure, M., Frye, C., Hattier, T., Phelps, R., Haugen-Strano, A., Katcher, H., Yakumo, K., Gholami, Z., Shaffer, D., Stone, S., Bayer, S., Wray, C., Bogden, R., Dayananth, P., Ward, J., Tonin, P., Narod, S., Bristow, P. K., Norris, F. H., Helvering, L., Morrison, P., Rosteck, P., Lai, M., Barrett, J. C., Lewis, C., Neuhausen, S., Cannon-Albright, L., Goldgar, D., Wiseman, R., Kamb, A., and Skolnick, M. H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (Wash. DC), 266: 66-71, 1994. (Pubitemid 24345325)
3. Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L. M., Haugen-Strano, A., Swensen, J., Miki, Y., Eddington, K., McClure, M., Frye, C., Weaver-Feldhaus, J., Ding, W., Gholami, Z., Soderkvist, P., Terry, L., Jhanwar, S., Berchuck, A., Iglehart, J. D., Marks, J., Ballinger, D. G., Barrett, J. C., Skolnick, M. H., Kamb, A., and Wiseman, R. BRCA1 mutations in primary breast and ovarian carcinomas. Science (Wash. DC), 266: 120-122, 1994. (Pubitemid 24345332)
4. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst., 90: 1371-1388, 1998. (Pubitemid 28439961)
5. Johannsson, O. T., Idvall, I., Anderson, C., Borg, A., Barkardottir, R. B., Egilsson, V., and Olsson, H. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer, 33: 362-371, 1997.
6. Osin, P., Crook, T., Powles, T., Peto, J., and Gusterson, B. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers. Lancet, 351: 1487, 1998. (Pubitemid 28227042)
7. Korach, K. S. Insights from the study of animals lacking functional estrogen receptor. Science (Wash. DC), 266: 1524-1527, 1994.
8. Lydon, J. P., DeMayo, F. J., Funk, C. R., Mani, S. K., Hughes, A. R., Montgomery, C. A., Jr., Shyamala, G., Conneely, O. M., and O'Malley, B. W. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev., 9: 2266-2278, 1995.
9. MacMahon, B., and Feinlieb, M. Breast cancer in relation to nursing and menopausal history. J. Natl. Cancer Inst., 24: 733-753, 1960.
10. Longacre, T. A., and Bartow, S. A. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am. J. Surg. Pathol., 10: 382-393, 1986. (Pubitemid 16066440)
11. Le Page, F., Randrianarison, V., Marot, D., Cabannes, J., Perricaudet, M., Feunteun, J., and Sarasin, A. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res., 60: 5548-5552, 2000.
12. Liehr, J. G. Is estradiol a genotoxic mutagenic carcinogen? Endocr. Rev., 21: 40-54, 2000. (Pubitemid 32260395)
13. Parodi, P. W. Cows' milk fat components as potential anticarcinogenic agents. J. Nutr., 127: 1055-1060, 1997. (Pubitemid 27242101)
14. Newmark, H. L., and Young, C. W. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J. Cell. Biochem., 22: 247-253, 1995.
15. Archer, S. Y., and Hodin, R. A. Histone acetylation and cancer. Curr. Opin. Genet. Dev., 9: 171-174, 1999. (Pubitemid 29158551)
16. Heerdt, B. G., Houston, M. A., Anthony, G. M., and Augenlicht, L. H. Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of the short-chain fatty acid butyrate, is associated with mitochondrial activity. Cancer Res., 59: 1584-15891, 1999.
17. Sowa, Y., and Sakai, T. Butyrate as a model for "gene-regulating chemoprevention and chemotherapy." Biofactors, 12: 283-287, 2000. (Pubitemid 32107417)
18. Belobrajdic, D. P., and McIntosh, G. H. Dietary butyrate inhibits NMU-induced mammary cancer in rats. Nutr. Cancer, 36: 217-223, 2000. (Pubitemid 30437043)
19. deFazio, A., Chiew, Y. E., Donoghue, C., Lee, C. S. L., and Sutherland, R. L. Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines. J. Biol. Chem., 267: 18008-18012, 1992.
20. Graham, K. A., and Buick, R. N. Sodium butyrate induces differentiation in breast cancer cell lines expressing the estrogen receptor. J. Cell. Physiol., 136: 63-71, 1988.
21. Horwitz, K. B., Mockus, M. B., and Lessey, B. A. Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell, 28: 633-642, 1982. (Pubitemid 12111931)
22. Abe, M., and Kufe, D. W. Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells. Cancer Res., 44: 4574-4577, 1984. (Pubitemid 14008780)
23. Abe, M., and Kufe, D. W. Effect of sodium butyrate on human breast carcinoma (MCF-7) cellular proliferation, morphology, and CEA production. Breast Cancer Res. Treat., 4: 269-274, 1984. (Pubitemid 15189795)
24. Boffa, L., Vidali, G., Mann, R., and Allfrey, V. Suppression of histone deacetylation in vivo by sodium butyrate. J. Biol. Chem., 253: 3364-3366, 1978. (Pubitemid 8349780)
25. Xu, L., Glass, C. K., and Rosenfeld, M. G. Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet. Dev., 9: 140-147, 1999. (Pubitemid 29158546)
26. Kramer, O. H., Gottlicher, M., and Heinzel, T. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab., 12: 294-300, 2001. (Pubitemid 33714220)
27. Lallemand, F., Courilleau, D., Sabbah, M., Redeuilh, G., and Mester, J. Direct inhibition of the expression of cyclin D1 by sodium butyrate. Biochem. Biophys. Res. Commun., 229: 163-169, 1996. (Pubitemid 27013725)
28. Vaziri, C., Stice, L., and Faller, D. V. Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein mediated signals. Cell Growth Differ., 9: 465-474, 1998. (Pubitemid 28345871)
29. Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., and Weinberg, R. A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell, 82: 621-630, 1995.
30. Fantl, V., Stamp, G., Andrews, A., Rosewell, I., and Dickson, C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev., 9: 2364-2372, 1995.
31. Gorospe, M., Shack, S., Guyton, K. Z., Samid, D., and Holbrook, N. J. Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ., 7: 1609-1615, 1996. (Pubitemid 26415156)
32. Schwartz, B., Avivi-Green, C., and Polak-Charcon, S. Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells. Mol. Cell. Biochem., 188: 21-30, 1998. (Pubitemid 28493314)
33. Collins, A. F., Pearson, H. A., Giardina, P., McDonagh, K. T., Brusilow, S. W., and Dover, G. J. Oral sodium phenylbutyrate therapy in homozygous β-thalassemia: a clinical trial. Blood, 85: 43-49, 1995.
34. Dover, G. J. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea. Ann. NY Acad. Sci., 850: 80-86, 1998.
35. Conley, B. A., Egorin, M. J., Tait, N., Rosen, D. M., Sausville, E. A., Dover, G., Fram, R. J., and Van Echo, D. A. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin. Cancer Res., 4: 629-634, 1998. (Pubitemid 28193561)
36. Carducci, M. A., Gilbert, J., Bowling, M. K., Noe, D., Eisenberger, M. A., Sinibaldi, V., Zabelina, Y., Chen, T. L., Grochow, L. B., and Donehower, R. C. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res., 7: 3047-3055, 2001. (Pubitemid 32963823)
37. Gilbert, J., Baker, S. D., Bowling, M. K., Grochow, L., Figg, W. D., Zabelina, Y., Donehower, R. C., and Carducci, M. A. A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res., 7: 2292-2300, 2001. (Pubitemid 32751627)
38. Carducci, M. A., Nelson, J. B., Chantack, K. M., Ayyagari, S. R., Sweatt, W. H., Campbell, P. A., Nelson, W. G., and Simmons, J. W. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res., 2: 379-387, 1996. (Pubitemid 26075641)
39. Davis, T., Kennedy, C., Chiew, Y. E., Clarke, C. L., and deFazio, A. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res., 6: 4334-4342, 2000.
40. Zeps, N., Bentel, J. M., Papadimitriou, J. M., D'Antuono, M. F., and Dawkins, H. J. Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth. Differentiation (Camb.), 62: 221-226, 1998. (Pubitemid 28165705)
41. Clarke, R. B., Howell, A., Potten, C. S., and Anderson, E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res., 57: 4987-4991, 1997. (Pubitemid 27498105)
42. Nelson, J. F., Felicio, L. S., Randall, P. K., Sims, C., and Finch, C. E. A longitudinal study of estrous cyclicity in aging C57BL/6J mice: I. Cycle frequency, length and vaginal cytology. Biol. Reprod., 27: 327-339, 1982. (Pubitemid 13230807)
43. deFazio, A., Leary, J., Hedley, D., and Tattersall, M. Immunohistochemical detection of proliferating cells in vivo. J. Histochem. Cytochem., 35: 571-578, 1987.
44. Armitage, P., and Berry, G. Statistical methods in medical research. Carlton, Victoria, Australia: Blackwell Scientific Publications, 1980.
45. Zysow, B. R., Kauser, K., Lawn, R. M., and Rubanyi, G. M. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. Arterioscler. Thromb. Vasc. Biol., 17: 1741-1745, 1997. (Pubitemid 27423996)
46. Yudkoff, M., Daikhin, Y., Nissim, I., Jawad, A., Wilson, J., and Batshaw, M. In vivo nitrogen metabolism in ornithine transcarbamylase deficiency. J. Clin. Investig., 98: 2167-2173, 1996. (Pubitemid 26376306)
47. Warrell, R. P. J., He, L-Z., Richon, V., Calleja, E., and Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst., 90: 1621-1625, 1998. (Pubitemid 28523436)
48. Nandi, S., Guzman, R. C., and Yang, J. Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc. Natl. Acad. Sci. USA, 92: 3650-3657, 1995.
49. McGuire, W. L. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin. Oncol., 5: 428-432, 1978.
50. Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., and Schmidt, E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (Lond.), 369: 669-671, 1994. (Pubitemid 24199473)
51. Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K. W., Musgrove, E. A., and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127-2133, 1993. (Pubitemid 23226946)
52. Yu, Q., Geng, Y., and Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature (Lond.), 411: 1017-1021, 2001. (Pubitemid 32612319)
53. Brodie, S. G., Xu, X., Qiao, W., Li, W. M., Cao, L., and Deng, C. X. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene, 20: 7514-7523, 2001. (Pubitemid 33086911)
54. Robson, M., Rajan, P., Rosen, P. P., Gilewski, T., Hirschaut, Y., Pressman, P., Haas, B., Norton, L., and Offit, K. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res., 58: 1839-1842, 1998. (Pubitemid 28217456)
55. Foster, J. S., Henley, D. C., Bukovsky, A., Seth, P., and Wimalasena, J. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol. Cell. Biol., 21: 794-810, 2001. (Pubitemid 32104728)
56. Lamb, J., Ladha, M. H., McMahon, C., Sutherland, R. L., and Ewen, M. E. Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol. Cell. Biol., 20: 8667-8675, 2000. (Pubitemid 32245900)
57. Castro-Rivera, E., Samudio, I., and Safe, S. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J. Biol. Chem., 276: 30853-30861, 2001.
58. Derjuga, A., Richard, C., Crosato, M., Wright, P. S., Chalifour, L., Valdez, J., Barraso, A., Crissman, H. A., Nishioka, W., Bradbury, E. M., and Th'ng, J. P. Expression of p21Waf1/Cip1 and cyclin D1 is increased in butyrate-resistant HeLa cells. J. Biol. Chem., 276: 37815-37820, 2001.
59. Kim, Y. B., Lee, K. H., Sugita, K., Yoshida, M., and Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene, 18: 2461-2470, 1999. (Pubitemid 29206159)
60. Courilleau, D., Chastre, E., Sabbah, M., Redeuilh, G., Atfi, A., and Mester, J. B-ind1, a novel mediator of Rac1 signaling, cloned from sodium butyrate-treated fibroblasts. J. Biol. Chem., 275: 17344-17348, 2000. (Pubitemid 30430769)
61. Joyce, D., Bouzahzah, B., Fu, M., Albanese, C., D'Amico, M., Steer, J., Klein, J. U., Lee, R. J., Segall, J. E., Westwick, J. K., Der, C. J., and Pestell, R. G. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-κB-dependent pathway. J. Biol. Chem., 274: 25245-25249, 1999.
62. Yin, L., Laevsky, G., and Giardina, C. Butyrate suppression of colonocyte NF-κB activation and cellular proteasome activity. J. Biol. Chem., 276: 44641-44646, 2001.
63. Inan, M. S., Rasoulpour, R. J., Yin, L., Hubbard, A. K., Rosenberg, D. W., and Giardina, C. The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line. Gastroenterology, 118: 724-734, 2000. (Pubitemid 30171622)
64. Segain, J. P., Raingeard de la Bletiere, D., Bourreille, A., Leray, V., Gervois, N., Rosales, C., Ferrier, L., Bonnet, C., Blottiere, H. M., and Galmiche, J. P. Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut, 47: 397-403, 2000.
65. Biswas, D. K., Dai, S. C., Cruz, A., Weiser, B., Graner, E., and Pardee, A. B. The nuclear factor κB (NF-κB): a potential therapeutic target for estrogen receptor negative breast cancers. Proc. Natl. Acad. Sci. USA, 98: 10386-10391, 2001. (Pubitemid 32803029)
66. Coradini, D., Pellizzaro, C., Miglierini, G., Daidone, M. G., and Perbellini, A. Hyaluronic acid as drug delivery for sodium butyrate improvement of the anti-proliferative activity on a breast-cancer cell line. Int. J. Cancer, 81: 411-416, 1999. (Pubitemid 29165200)
67. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. G., and Heinzel, T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J., 20: 6969-6978, 2001. (Pubitemid 34062289)
68. Cohen, L. A., Amin, S., Marks, P. A., Rifkind, R. A., Desai, D., and Richon, V. M. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res., 19: 4999-5005, 1999. (Pubitemid 30103315)